Primary |
Metastases To Bone |
100.0% |
|
Osteonecrosis Of Jaw |
100.0% |
|
Secondary |
Product Used For Unknown Indication |
37.1% |
Multiple Myeloma |
13.4% |
Osteoporosis |
9.3% |
Breast Cancer Metastatic |
8.2% |
Drug Use For Unknown Indication |
8.2% |
Metastases To Bone |
5.2% |
Prostate Cancer |
4.1% |
Plasma Cell Myeloma |
3.1% |
Chemotherapy |
2.1% |
Diarrhoea |
2.1% |
Lung Neoplasm Malignant |
2.1% |
Breast Neoplasm |
1.0% |
Nausea |
1.0% |
Pain |
1.0% |
Respiratory Disorder |
1.0% |
Vomiting |
1.0% |
|
Osteonecrosis Of Jaw |
25.8% |
Osteonecrosis |
12.9% |
Neuropathy Peripheral |
9.7% |
Renal Cyst |
9.7% |
Infection |
6.5% |
Oroantral Fistula |
3.2% |
Renal Tubular Necrosis |
3.2% |
Skin Exfoliation |
3.2% |
Swelling |
3.2% |
Tooth Extraction |
3.2% |
Tooth Loss |
3.2% |
Upper Limb Fracture |
3.2% |
Urge Incontinence |
3.2% |
Visual Impairment |
3.2% |
Vomiting |
3.2% |
Wound Complication |
3.2% |
|
Concomitant |
Multiple Myeloma |
22.4% |
Product Used For Unknown Indication |
12.2% |
Drug Use For Unknown Indication |
9.7% |
Prophylaxis |
9.7% |
Hypertension |
7.0% |
Breast Cancer |
4.7% |
Pain |
4.3% |
Plasma Cell Myeloma |
4.3% |
Breast Cancer Metastatic |
4.2% |
Diarrhoea |
3.2% |
Arthritis |
3.0% |
Bone Pain |
2.8% |
Hypoparathyroidism |
2.3% |
Metastases To Bone |
1.8% |
Osteoporosis Prophylaxis |
1.7% |
Antiviral Prophylaxis |
1.3% |
Atrial Fibrillation |
1.3% |
Hypothyroidism |
1.3% |
Supplementation Therapy |
1.3% |
Hypercalcaemia |
1.2% |
|
Thrombocytopenia |
19.5% |
Renal Failure Acute |
7.8% |
Septic Shock |
7.8% |
Ventricular Fibrillation |
6.5% |
Intestinal Obstruction |
5.2% |
Multiple Myeloma |
5.2% |
Pain |
5.2% |
Urinary Tract Infection |
5.2% |
Pyrexia |
3.9% |
Renal Failure |
3.9% |
Renal Impairment |
3.9% |
Subdural Haematoma |
3.9% |
Tachycardia Paroxysmal |
3.9% |
Dermatitis Psoriasiform |
2.6% |
Dyspnoea |
2.6% |
Electrolyte Imbalance |
2.6% |
Femoral Neck Fracture |
2.6% |
Gastritis |
2.6% |
Hyponatraemia |
2.6% |
Localised Infection |
2.6% |
|